Dognosis sells dog noses as a cancer prescreen. The caveats are the actual story

Dognosis, a two-year-old Bengaluru company, is turning trained sniffer dogs into a data product: patients breathe into a mask, the sample is couriered to a farm outside the city, and beagles, labradors and Dutch shepherds sniff it while sensors and AI record their movements, respiration, brain activity and body language as structured data ^[1][2][3]. What makes this worth an operator's attention is not the dogs but the framing the company itself uses, which is that this is a prescreening tool in trials rather than a diagnostic ^[19][18].

The biological premise is that tumours leave a chemical signature in exhaled breath that a dog can smell earlier than conventional tools can see it ^[4]. The AI layer is the standardisation step, converting an animal's reaction into something repeatable, and there is no imaging, blood draw or biopsy in the workflow ^[3][5]. Founder Akash Kulgod says the approach targets more than 20 cancer types across seven groups, including breast, oral cavity, lung and cervical ^[6].

The reported numbers are the part to hold at arm's length. In Phase 2 trials published in the Journal of Clinical Oncology, Dognosis reports roughly 90% sensitivity for early-stage cancers, and says dogs trained on 10 cancer types went on to flag an 11th they had never been shown ^[7][8]. Those accuracy and detection figures come from the company and its researchers rather than independent confirmation ^[9]. A Phase 3 trial began in April across 10 hospitals, aiming for about 10,000 participants ^[15].

The market logic is stronger than the evidence base, and it is legitimate. India logged about 1.5 million new cancer cases and more than 900,000 deaths in 2024 ^[10], a deaths-to-cases ratio of roughly 60% ^[21]. Roughly 1.9% of women are screened for cervical cancer and fewer than 1% for breast or oral cancers, with cost, distance and the discomfort of invasive tests doing most of the work in that gap ^[11][12]. Dognosis raised a $1.5m pre-seed in 2024 and has closed a further undisclosed round, with Accel India and Caffeinated Capital among its backers; neither has put a figure on the latest raise ^[13].

Now the regulatory wrinkle. Kulgod says Dognosis needs no Indian regulatory approval because a prescreening tool is not classed as a diagnostic device ^[18]. That is a real launch advantage and a real exposure: the product can reach patients without clearing the bar a diagnostic would face, which puts the entire burden on communicating that a positive result is a prompt to see a doctor, not a verdict ^[18][19]. Anyone assessing AI health claims should read the classification as a business decision, not a technical one.

The operational plan is where the arithmetic gets tight. Kulgod plans an at-home multi-cancer prescreen in India next year at a few thousand rupees, scaling to a million tests a year on a one-week turnaround with about 30 dogs ^[14][16]. That implies roughly 33,000 samples per dog per year, or about 91 a day with no rest days ^[22]. Unsurprisingly, the stated endgame is replacing the dogs with sensors ^[20].

Watch the Phase 3 readout and whether anyone outside the company reproduces the sensitivity figure ^[15][9]. Watch the per-dog throughput as launch approaches ^[22]. And watch the planned US facility in late 2027 or early 2028, where the prescreen-versus-diagnostic distinction will not be the company's to define ^[17][18].